about
Modifications of antiepileptic drugs for improved tolerability and efficacyTiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's diseaseSynthesis and Anticonvulsant Evaluation of some New 6-(Substituted-phenyl)thiazolo[3,2-b][1,2,4]triazole Derivatives in MiceSynthesis and anticonvulsant properties of new mannich bases derived from 3,3-disubstituted pyrrolidine-2,5-diones. Part IV.Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI)Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics.Randomized Comparative Bioavailability of a Novel Three-Dimensional Printed Fast-Melt Formulation of Levetiracetam Following the Administration of a Single 1000-mg Dose to Healthy Human Volunteers Under Fasting and Fed ConditionsLocally applied valproate enhances survival in rats after neocortical treatment with tetanus toxin and cobalt chloride.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.Recent advances in the chemistry and biology of benzothiazoles.New benzo[d]thiazol-2-yl-aminoacetamides as potential anticonvulsants: synthesis, activity and prediction of molecular properties.Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation.Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsyFirst report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis.Effect of experimentally induced hepatic and renal failure on the pharmacokinetics of topiramate in rats.Phenobarbital but Not Diazepam Reduces AMPA/kainate Receptor Mediated Currents and Exerts Opposite Actions on Initial Seizures in the Neonatal Rat Hippocampus.Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures.Novel derivatives of phthalimide with potent anticonvulsant activity in PTZ and MES seizure models.A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control.Docking studies of phthalimide pharmacophore as a sodium channel blocker.C5 and C7 intramolecular hydrogen bonds stabilize the structure of N-pyrazinoyl-gabapentin (Pyr-Gpn-OH).Design, synthesis, and anticonvulsant activity evaluation of 4-(3-alkoxy-phenyl)-2,4-dihydro-[1,2,4]triazol-3-ones.Synthesis and evaluation of the anticonvulsant activity of 8-alkoxy-4,5-dihydrobenzo[b][1,2,4]triazolo[4,3-d][1,4]thiazepine derivatives.Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control.Pharmacokinetics of gabapentin in horses.Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.Recent developments on triazole nucleus in anticonvulsant compounds: a review.Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome.Development of an (S)-1-{2-[Tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic acid [(S)-SNAP-5114] Carba Analogue Inhibitor for Murine γ-Aminobutyric Acid Transporter Type 4
P2860
Q24651951-990284F6-6425-49FE-8CB5-DF86F67F83A3Q33327216-A9A97A3D-2FC6-4940-B8AD-783990996CDDQ34146110-6F68D455-E803-4AD4-B547-70C96A42E254Q34295248-5460F240-114F-4D9E-9E3D-BB7600203946Q35156078-0F0D021A-03B1-4025-A0A4-E56EFEB9F99EQ35776244-F0FDA6C8-4B6C-47C9-9E54-16B87B13F20FQ36924020-EB27BFF1-5374-48E7-9728-877447D5E69CQ37208627-CE068A0E-8852-4F1B-BC60-4F38F96A1EECQ38181565-1EDD6492-E58F-4502-AC03-F39B6C0920E0Q38355999-B0F940D0-E48F-4E1F-A46F-6B0CF7876118Q39028182-F9E32339-BF96-4AB7-8326-3E6DEE408B43Q39226319-B492C04A-9490-4B40-A87E-349633C27B0DQ39238316-19FCF428-D8AE-4057-87EB-5CC4653894ECQ40342657-E90C00B3-7BBF-4B99-B19B-0F4AB4C5D5BFQ41151476-05239EC7-1CB4-44F5-BD81-5745DE274F6BQ41774263-C1268B11-DC90-420A-BB94-CF9AD1BF6B42Q42019208-B0F42D7B-4988-4F50-B363-4E5B3989C77FQ42071580-31E3D110-A83D-4D85-AEDD-415A113F3269Q42372617-51B3183C-93B5-45FA-B78E-2308DE5343E1Q42939077-FA479217-7B1E-4276-9A9A-25D6B6F0BF52Q43833629-98D4DD8F-717A-49FA-A9E2-26D3982BF7B9Q44033948-2A95359A-28BF-490B-AD2A-CF93BCBA214CQ45194356-965DDC67-3B53-4656-963D-6AC0E5E2D04FQ46365421-88C8C074-E598-4079-8B58-11CDCB4799A0Q46728006-F87DC0B6-B0BC-4403-8626-D0747A394F4EQ47310442-B48FCFDC-366A-40A4-BC93-9F3D59040A6CQ49564600-06F08F6C-E4F3-4D02-8AA2-EBB569A5E175Q51737948-A2E041EA-8190-4879-9994-0C64E041C162Q59157179-031008D1-3F97-4C58-BB91-78A18B058479
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Novel anticonvulsant drugs.
@ast
Novel anticonvulsant drugs.
@en
type
label
Novel anticonvulsant drugs.
@ast
Novel anticonvulsant drugs.
@en
prefLabel
Novel anticonvulsant drugs.
@ast
Novel anticonvulsant drugs.
@en
P1476
Novel anticonvulsant drugs.
@en
P2093
T J Feuerstein
P304
P356
10.1016/J.PHARMTHERA.2006.07.005
P577
2006-10-09T00:00:00Z